Welcome to our dedicated page for Pediatrix Medical Group news (Ticker: MD), a resource for investors and traders seeking the latest updates and insights on Pediatrix Medical Group stock.
Pediatrix Medical Group, Inc. provides physician services for women, babies and children across hospital settings and office-based practices. Its recurring updates center on obstetrics, maternal-fetal medicine, neonatology, neonatal intensive care unit activity and other pediatric subspecialties, with revenue concentrated in neonatology and pediatric subspecialty care.
Company news also covers quarterly operating results, same-unit revenue trends, reimbursement and payor-mix factors, patient acuity, hospital contract administrative fees, practice acquisitions and dispositions, service expansions, clinical quality initiatives and neonatology education through NEO: The Conference for Neonatology.
Pediatrix Medical Group (NYSE: MD) reported first-quarter 2026 results: net revenue $476.2M, net income $29.6M (EPS $0.36), Adjusted EPS $0.44, and Adjusted EBITDA $58.2M. Same-unit revenue rose 2.8% driven by reimbursement improvements; patient volume declined 1.6%.
Cash was $205.8M at March 31, 2026; total debt was $591M. The company reaffirmed 2026 Adjusted EBITDA guidance of $280M–$300M.
Pediatrix Medical Group (NYSE: MD) will hold a first-quarter 2026 investor conference call and webcast on Tuesday, May 5, 2026 at 9:00 a.m. ET to discuss results for the quarter ended March 31, 2026. A detailed press release will be issued the morning of May 5, 2026 before markets open.
Investors can access the live webcast at www.pediatrix.com/investors.
Pediatrix (NYSE: MD) expanded maternal-fetal medicine services in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine announced March 26, 2026.
The practice will operate as Maternal-Fetal Medicine Specialists of Tennessee across five Greater Nashville locations, adding four board-certified physicians and six advanced practice providers. The deal was a cash transaction and is expected to be immediately accretive to earnings; no further financial terms were disclosed.
Pediatrix (NYSE: MD) announced two senior clinical hires on March 24, 2026: James Barry, M.D., MBA, as Chief Clinical Quality & Transformation Officer and Jochen Profit, M.D., MPH, as Chief Quality Advisor. Both leaders will advance clinical quality, oversee CREQS activities, and support research, safety and systemwide improvement.
The appointments emphasize pediatrix's focus on evidence-based care, neonatology expertise, artificial intelligence in medicine, and national quality collaborations to improve outcomes and provider satisfaction.
Pediatrix Medical Group (NYSE: MD) will host the 47th annual NEO: The Conference for Neonatology in Las Vegas, Feb. 25–27, 2026. The event gathers neonatal‑perinatal experts for sessions on clinical advances, neonatal POCUS training, ethics, respiratory care, nutrition, and accredited continuing education credits.
Pediatrix Medical Group (NYSE: MD) reported Q4 2025 results with net revenue $493.8M, net income $33.7M ($0.40 diluted) and Adjusted EBITDA $65.8M. For full-year 2025, revenue was $1.91B, net income $165.4M and Adjusted EBITDA $275.6M. Cash was $375.2M at year-end and the company repurchased $64.0M of shares in Q4.
Preliminary 2026 outlook targets Adjusted EBITDA $280M–$300M. Management cited same-unit revenue growth of 4.0% and higher variable practice incentive compensation as a headwind to margins.
Pediatrix Medical Group (NYSE: MD) will host an investor conference call and webcast on Thursday, February 19, 2026 at 9:00 a.m. ET to discuss results of operations for the quarter ended December 31, 2025. A detailed press release will be issued the morning of February 19, 2026 before markets open. The webcast will be available at the company investor website.
Pediatrix Medical Group (NYSE: MD) reported Q3 2025 results with net revenue $492.9M, net income $71.7M (diluted EPS $0.84) and Adjusted EBITDA $87.3M. Adjusted EPS was $0.67. Management raised full-year 2025 Adjusted EBITDA guidance to $270M–$290M. Q3 results reflected higher same-unit reimbursement (+7.6%) and same-unit revenue growth of 8.0%, partially offset by non-same unit practice dispositions. Cash and equivalents were $340.1M, total debt $602M, and operating cash from continuing operations was $138.1M in Q3. The company used cash for $20.9M share repurchases and $19.2M of acquisitions.
Pediatrix Medical Group (NYSE: MD) will host an investor conference call and webcast on Monday, November 3, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended September 30, 2025. A detailed press release will be issued the morning of November 3, 2025 before markets open.
The live webcast will be accessible via Pediatrix’s investor site at www.pediatrix.com/investors.
Pediatrix Medical Group (NYSE:MD) has announced a significant $250 million share repurchase program authorized by its Board of Directors. The program, which has a three-year term, demonstrates the company's confidence in its financial position, highlighted by strong cash flow, healthy cash balances, and low debt levels.
CEO Mark S. Ordan emphasized that the company will implement the program opportunistically while evaluating other strategic cash deployment options. The repurchases may be executed through private negotiations or open market transactions, following Rule 10b5-1 and/or Rule 10b-18 guidelines, with timing and volume dependent on market conditions and other factors.